Idarubicin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1990
- First approval year
- 1990
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Idarubicin
- Molecular weight
- 497.5
- Structure (SMILES)
- CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
- (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE
- 1s 3s 3 acetyl 1 2 3 4 6 11 hexahydro 3 5 12 trihydroxy 6 11 dioxo 1 naphthacenyl 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranoside
- 5 12 naphthacenedione 9 acetyl 7 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranosyl oxy 7 8 9 10 tetrahydro 6 9 11 trihydroxy 7s 9s
- 5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-, (7S,9S)-
- idarubicin
- Idarubicin
- idarubicin [INN]
- IDARUBICIN [MI]
- IDARUBICIN [VANDF]
- Idarubicin [WHO-DD]
- idarubicin inn
- idarubicin mi
- idarubicin vandf
- idarubicin who dd
- idarubicina
- Idarubicina
- idarubicine
- Idarubicine
- IDARUBICINE
- zavedos
- ZAVEDOS
- ATC classification codes
- L01DB06
Sources for recorded values
- CAS registry numbers
- 58957-92-9
- ChEMBL ID
- CHEMBL1117
- InChIKey
- XDXDZDZNSLXDNA-TZNDIEGXSA-N
- PubChem compound IDs
- 42890
- RxNorm IDs (RxCUI)
- 5650
- FDA ingredient codes (UNII)
- ZRP63D75JW
- Applicant
- PFIZER
- Approval date
- 27 Sept 1990
- Application number
- NDA050661
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- idarubicin
- Type
- Natural product
- Drug name stem
- -rubicin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Open Targets mechanisms
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TOP2A
- Protein identifier
- P11388
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Erythroblastic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000218
- Subject identifier
- D004915
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Monocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000221
- Subject identifier
- D007948
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia, Myelomonocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000223
- Subject identifier
- D015479
- Condition
- Leukemia, Promyelocytic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000224
- Subject identifier
- D015473
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Myeloproliferative Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002428
- Subject identifier
- D009196
- Condition
- Leukemia, Megakaryoblastic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003025
- Subject identifier
- D007947
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003027
- Subject identifier
- D015470
- Condition
- Anemia, Refractory
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003802
- Subject identifier
- D000753
- Condition
- Anemia, Refractory, with Excess of Blasts
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003811
- Subject identifier
- D000754
- Condition
- Myeloproliferative Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004251
- Subject identifier
- D009196
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Leukemia, Erythroblastic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001257
- Subject identifier
- D004915
- Condition
- Leukemia, Myelomonocytic, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001779
- Subject identifier
- D015477
- Condition
- Sarcoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001968
- Subject identifier
- D012509
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0000873
- Subject identifier
- D054198
And 3 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000224
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000157
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001968
- Highest recorded phase
- 3
- Condition identifier
- HP_0002863
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000814
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000872
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000873
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002691
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003539
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004643
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004947
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004947
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004963
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 2
And 38 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- 5'nucleotidase increased
- Reports
- 4
- Reporting signal score
- 23.6707
- Event
- acute lymphocytic leukaemia recurrent
- Reports
- 18
- Reporting signal score
- 61.468
- Event
- acute myeloid leukaemia
- Reports
- 43
- Reporting signal score
- 114.994
- Event
- acute myeloid leukaemia recurrent
- Reports
- 20
- Reporting signal score
- 86.0432
- Event
- acute promyelocytic leukaemia differentiation syndrome
- Reports
- 24
- Reporting signal score
- 125.415
- Event
- acute respiratory distress syndrome
- Reports
- 14
- Reporting signal score
- 19.8565
- Event
- adenomatous polyposis coli
- Reports
- 5
- Reporting signal score
- 23.5056
- Event
- aeromonas infection
- Reports
- 6
- Reporting signal score
- 28.3
- Event
- aplasia
- Reports
- 10
- Reporting signal score
- 25.8459
- Event
- aspergillus infection
- Reports
- 13
- Reporting signal score
- 29.1045
- Event
- bacteraemia
- Reports
- 25
- Reporting signal score
- 49.2995
- Event
- blood bilirubin increased
- Reports
- 21
- Reporting signal score
- 20.2883
- Event
- bone marrow failure
- Reports
- 58
- Reporting signal score
- 115.349
- Event
- bronchopulmonary aspergillosis
- Reports
- 39
- Reporting signal score
- 121.037
- Event
- cholecystitis
- Reports
- 13
- Reporting signal score
- 19.3979
- Event
- cholecystitis acute
- Reports
- 13
- Reporting signal score
- 26.5728
- Event
- chorioretinal disorder
- Reports
- 5
- Reporting signal score
- 19.4619
- Event
- chromosomal deletion
- Reports
- 4
- Reporting signal score
- 17.0692
- Event
- clostridium difficile colitis
- Reports
- 13
- Reporting signal score
- 18.7747
- Event
- colitis
- Reports
- 22
- Reporting signal score
- 20.5154
- Event
- cranial nerve infection
- Reports
- 3
- Reporting signal score
- 17.3906
- Event
- cytomegalovirus infection
- Reports
- 19
- Reporting signal score
- 26.3861
- Event
- cytomegalovirus infection reactivation
- Reports
- 15
- Reporting signal score
- 45.0331
- Event
- cytopenia
- Reports
- 16
- Reporting signal score
- 26.6699
- Event
- dedifferentiated liposarcoma
- Reports
- 7
- Reporting signal score
- 44.3438
And 65 more, listed on the interactive page.
- NCT00002517
- NCT00002532
- NCT00002549
- NCT00002609
- NCT00002658
- NCT00002701
- NCT00002719
- NCT00002761
- NCT00002771
- NCT00002800
- NCT00002812
- NCT00002816
- NCT00002868
- NCT00002926
- NCT00002945
- NCT00002989
- NCT00003178
- NCT00003268
- NCT00003405
- NCT00003602
- NCT00003729
- NCT00003758
- NCT00003783
- NCT00004905
- NCT00005823
And 129 more, listed on the interactive page.
- Dose
- 12 mg/m2
- Route
- Intravenous
- How often
- Days 1, 2, and 3 of induction
Conditions of use
- Administer over 10 to 15 minutes
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 5
- Polar surface area
- 176.61
- Calculated partition coefficient (ALogP)
- 1.02
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 36
- Molecular formula
- C26H27NO9
- Monoisotopic mass
- 497.16858144
- Natural product
- Yes
- Recorded assays
- 1,792
- Active assays
- 289
- Confirmatory
- Other
- Screening
- Summary
- Antibiotics, Antineoplastic
- Topoisomerase II Inhibitors
Oral bioavailability
- Median
- 28
- Mean
- 28
- Minimum
- 28
- Maximum
- 28
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (211)
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
- A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Adoptive Transfer of Haplo-identical DLI for AML and MDS
- Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
- AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Alisertib for Acute Myeloid Leukemia
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Approved for (2)
- Acute myeloid leukemia by FAB classification
- Neoplasm
In development for (53)
- Acute erythroid leukemia Phase 3
- Acute leukemia Phase 2
- Acute leukemia of ambiguous lineage Phase 2
- Acute lymphoblastic leukemia Phase 3
- Acute megakaryoblastic leukemia Phase 3
- Acute monocytic leukemia Phase 3
- Acute myeloblastic leukemia without maturation Phase 3
- Acute myeloid leukemia Phase 3
- Acute myelomonocytic leukemia M4 Phase 3
- Acute promyelocytic leukemia Phase 3
- Alveolar rhabdomyosarcoma Phase 3
- B-cell acute lymphoblastic leukemia Phase 2
- B-cell adult acute lymphocytic leukemia Phase 2
- B-cell childhood acute lymphoblastic leukemia Phase 2
- Bone marrow neoplasm Phase 3
- Burkitt lymphoma Phase 3
- CD4+/CD56+ hematodermic neoplasm Phase 2
- Chronic myeloid leukemia Phase 2
- Chronic myelomonocytic leukemia Phase 3
- Diffuse large B-cell lymphoma Phase 3
Other linked conditions (1)
- Anaplastic large cell lymphoma
Targets (1)
- TOP2A DNA topoisomerase II alpha inhibitor